Simplify Asset Management Inc. Makes New Investment in Jasper Therapeutics, Inc. $JSPR

Simplify Asset Management Inc. bought a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the third quarter, Holdings Channel.com reports. The fund bought 609,053 shares of the company’s stock, valued at approximately $1,450,000.

A number of other large investors have also recently made changes to their positions in JSPR. Acadian Asset Management LLC bought a new position in shares of Jasper Therapeutics in the first quarter worth about $46,000. Marex Group plc purchased a new stake in Jasper Therapeutics in the 2nd quarter valued at about $74,000. Engineers Gate Manager LP bought a new position in Jasper Therapeutics in the 2nd quarter worth about $78,000. XTX Topco Ltd purchased a new position in shares of Jasper Therapeutics during the second quarter worth approximately $152,000. Finally, Marshall Wace LLP purchased a new position in shares of Jasper Therapeutics during the second quarter worth approximately $281,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $1.76 on Tuesday. Jasper Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $22.52. The business has a fifty day moving average price of $1.88 and a 200 day moving average price of $2.80. The stock has a market capitalization of $49.24 million, a P/E ratio of -0.30 and a beta of 3.06.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12). As a group, equities research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JSPR. Evercore ISI lowered their price target on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. JMP Securities dropped their price target on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Monday, September 22nd. Finally, BTIG Research decreased their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Hold” and an average price target of $20.29.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.